Magnetic Resonance Imaging (MRI) technology is most commonly associated with the medical industry and is used to create detailed images of organs and tissues within the body, but Nanalysis Scientific (TSXV:NSCI) Companies such as are expanding the horizons of MRI capabilities. .
Nanalys is a Calgary-based company that develops and manufactures compact MRI and nuclear magnetic resonance (NMR) equipment for clinical, laboratory, and industrial markets.
Of particular note, these portable devices do not require liquid helium or other cryogens and have been used in various industries such as medical, pharmaceutical, biotechnology, mining, oil and gas, as well as government and university research around the world. It can also be used by institutions.
In an interview with The Market Online, Nanalysys Scientific CEO Sean Krakiwski explained that the company has expanded its range of products and services to reach a broader market. It added that the pharmaceutical market remains the company's largest vertical industry.
In other words, Nanalysys Scientific presents itself as a unique business serving a variety of sectors, providing investors with exposure to industries they would not otherwise have.
As the company continues to ramp up its efforts, The Market Online takes a closer look at Nanaracy, its product offering, what the future has in store, and what makes it a sound investment opportunity.
Nanalysis details
Founded in 2009, Nanalysys Scientific's business model is what the company calls “industrial MRI and NMR.” The company develops and manufactures portable NMR spectrometers or analyzers for the laboratory and industrial markets.
In short, thanks to its technology, Nanaracy helps analysts identify and understand essential items for industrial and commercial purposes. This includes being able to detect whether something is branded correctly, such as whether extra virgin olive oil is the real deal or an inferior imitation diluted with soybean oil.
The company's technology can also determine whether a fish supplement contains questionable ingredients or whether a pill picked up on the street is a modified illegal drug.
“Major pharmaceutical companies, food [companies] petrochemicals, advanced materials, [and] Many universities use our portable MRI machines to accurately determine molecules in target substances, including new drugs being designed by companies like Pfizer and Eli Lilly. ” Krakiwski told Market Online. “Portable magnetic resonance devices can also detect the amount of THC in cannabis oil or the amount of lithium in a lithium brine pool.”
All of this means that Nanalysys Scientific's technology is shaping the way pharmaceutical companies develop drugs and helping industrial chemists decide whether a chemical reaction is legitimate.
Notably, the company's main products are 60 MHz and 100 MHz portable magnetic resonance machines, of which Nanalysys has sold more than 1,200 units, according to Krakiwski.
The 60 MHz Benchtop product is the company's flagship all-in-one compact benchtop magnetic resonance spectrometer that can be taken anywhere and is truly easy to access. The platform comes with an easy-to-use interface controlled by a touch screen, keyboard and mouse, or an external computer with data easily retrieved by the user.
Source: Nanalysys Scientific
100 MHz products, on the other hand, increase productivity with fast and accurate results. This product is also the leading high-field NMR console on the market, giving users access to more information with better peak dispersion and resolution.
Source: Nanalysys Scientific
From a geographic perspective, Krakiwski explained, Nanalies'. Currently, the most important market is the United States, where the company has the largest presence. Nanalysys also sells directly in some parts of Europe, and has plans to expand direct sales to other international markets such as Japan, India, and even Indonesia, and currently sells through a network of local dealers. Is going.
Nanalysys competitive advantage
Krakiwski told The Market Online that the company's core technology platform is where it really shines.
Unlike most other MRI machines, what sets these products apart is their size. If you've ever had an MRI scan, you know that most MRI machines require a large, dedicated room. The Nanalysis machine is a fraction of the size and is portable.
However, despite their small size, the company's machines are powerful in their own right. This makes the machine easy to sell to universities, laboratories, and small businesses.
“[Nanalysis’ advantage] it is? [it] ” has been the most successful at scaling the technology down, Krakiwski told Market Online, adding that only one or two other companies have been able to scale the technology down. No one has been as successful as me.”
Krakiwski explained that all of the technology developed by the company is protected by patents, and that Nanalysys Scientific does all its own manufacturing to protect its intellectual property.
As of February, the company has more than 10 patents granted or pending in the United States. Patents protect innovations in technology and give their owners exclusive rights to their property, so others cannot make, use, offer for sale, sell, or import the claimed invention into the United States.
Fourth quarter and full year 2023 financial results
The company announced its fourth quarter and full-year 2023 financial results in late April. In the fourth quarter of 2023, Nanalysys Scientific demonstrated continued quarter-over-quarter revenue growth, due in part to expansion in airport security projects.
“The company's Security Services division will complete handover of all essential services for the company's airport security project in early 2024, and the project will continue to expand and deploy, moving towards achieving full profitability throughout the year. We're going to build it.''Additionally, there were significant upfront training costs in 2023, which reduced profits. We expect this to decline significantly in 2024, and we expect security services margins to improve throughout the year. ” Mr. Krakiwski said in his statement.
The company also achieved a new quarterly revenue record of $9.8 million due to continued expansion of security services related to Nanaracy&CloseCurlyQuote. Airport development project.
Nanalysys also completed a phase-in period in January related to the Airport Security Maintenance Project, resulting in the Security Services business performing maintenance on passenger screening imaging and detection equipment across Canada to meet anticipated operating rates. We have begun a scale-up phase to increase revenue. .
The future of Nanalysis Scientific
Investors can look to some catalysts and milestones as 2024 continues and eventually 2025 as Nanalysys considers possible expansion into other markets.
Krakiwski said investors can expect partnership announcements from the company as well as announcements related to regulatory changes on how the company's flagship product will encourage drug companies to adopt this new technology.
“[There will also be] continuous growth [the company’s] “On the service side of our business,” he said.
However, the most important thing in 2024 is for Nanalysys Scientific to achieve profitability, which has not always been the case for the company.
management team
Sean Krakiwski, CEO
Krakiwski is the founder of Nanaracy Scientific, the third technology startup in 20 years. In his 20 years of this he has raised over $75 million in his equity funds.
Mr. Krakiwski previously founded and founded Acceleware (TSXV:AXE), a company that provides software solutions that leverage the parallel processing capabilities of multi-core GPUs/CPUs for the electronic design and oil and gas industries.
Krakiwski holds a Master's degree and a Bachelor of Science degree in electrical engineering from the University of Calgary. He was drafted by the NHL's Los Angeles Kings in 1986 and played on the farm for two years before returning to school in 1990.
Randall McRae, CFO
In addition to being an entrepreneur, Randall McRae has over 15 years of experience in public, private, and professional services firms. McRae earned his Bachelor of Commerce in Accounting from the University of Calgary in 2007 and received his Chartered Accountant designation in 2010.
McRae then completed Chartered Accountants Canada's thorough taxation program and was recognized as one of the top nine nationally in his class. Prior to his role at Scientific, McRae was a senior manager at a large accounting firm. He is also a former technology professional. He co-founded a services company and held senior positions at a publicly traded oilfield services company.
Julian Muller, CTO
Julien Muller has over 16 years of experience in the NMR/MRI technology market. He started RS2D in 2004 after he obtained a degree in Electronics and Systems Engineering at Strasbourg and researched and designed RS2D's first his NMR spectrometer solution.
From there, Mueller designed a custom MRI product using superconducting cryogen-free magnets and a high-field NMR console. In 2018, Muller released the fourth generation of his NMR/MRI spectrometers, offering the latest in his FPGA technology across the magnetic resonance product profile.
investment corner
As of this writing, Nanaracy Scientific Corp. has a market capitalization of CA$50.27 million and 111.72 million shares outstanding. Year-to-date, the company's stock has increased 9.76% to $0.45 as of market close on April 23rd.
Nanalysys, which trades on the TSX Venture Exchange, is a small-cap, high-tech company with technology that is transforming the pharmaceutical, industrial and other industries.
As Nanalysys prepares to strengthen its partnerships and expand its presence, and with many milestones expected this year, the company may be a good fit for your investment portfolio.
Join the discussion. Find out what everyone is saying about this microcap gold stock on the Nanaracy Scientific Corp. message board, and check out Stockhouse's stock forums and message boards.
This is sponsored content published on behalf of Nanaracy Scientific Corp. See the full disclaimer here.
